Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
CRSP Analyst Ratings
Moderate Buy
14 Buy
6 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CRSP Stock 12 Month Forecast
Average Price Target
$68.65
▲(46.75%Upside)
| Highest Price Target$105.00 | Average Price Target$68.65 | Lowest Price Target$35.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$44
Hold
-5.94%
Downside
Reiterated
06/10/25
Crispr Therapeutics AG's stock score reflects significant financial challenges and valuation concerns, offset somewhat by positive technical indicators and strategic corporate events. The company's reliance on collaborations for revenue and external funding for liquidity are key risks. However, recent partnerships and shareholder approvals offer some optimism for strategic growth.
Bernstein
―
Hold
―
Reiterated
06/19/25
Citizens JMP
$86
Buy
83.84%
Upside
Reiterated
06/18/25
William Blair
―
Buy
―
Reiterated
06/03/25
Leerink Partners
$58→$56
Buy
19.71%
Upside
Reiterated
05/21/25
Truist Financial
―
Buy
―
Reiterated
05/20/25
Needham
$81
Buy
73.15%
Upside
Reiterated
05/20/25
BMO Capital
$75
Buy
60.32%
Upside
Reiterated
05/20/25
Mizuho Securities
$99→$85
Buy
81.70%
Upside
Reiterated
05/20/25
Piper Sandler
$105
Buy
124.45%
Upside
Reiterated
05/20/25
H.C. Wainwright
$65
Buy
38.95%
Upside
Reiterated
05/20/25
Goldman Sachs
$57→$47
Hold
0.47%
Upside
Reiterated
05/19/25
Citi
$82
Buy
75.29%
Upside
Reiterated
05/19/25
Bank of America Securities
$79
Buy
68.88%
Upside
Reiterated
05/19/25
Barclays
$56→$42
Hold
-10.22%
Downside
Reiterated
05/09/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$44
Hold
-5.94%
Downside
Reiterated
06/10/25
Crispr Therapeutics AG's stock score reflects significant financial challenges and valuation concerns, offset somewhat by positive technical indicators and strategic corporate events. The company's reliance on collaborations for revenue and external funding for liquidity are key risks. However, recent partnerships and shareholder approvals offer some optimism for strategic growth.
Bernstein
―
Hold
―
Reiterated
06/19/25
Citizens JMP
$86
Buy
83.84%
Upside
Reiterated
06/18/25
William Blair
―
Buy
―
Reiterated
06/03/25
Leerink Partners
$58→$56
Buy
19.71%
Upside
Reiterated
05/21/25
Truist Financial
―
Buy
―
Reiterated
05/20/25
Needham
$81
Buy
73.15%
Upside
Reiterated
05/20/25
BMO Capital
$75
Buy
60.32%
Upside
Reiterated
05/20/25
Mizuho Securities
$99→$85
Buy
81.70%
Upside
Reiterated
05/20/25
Piper Sandler
$105
Buy
124.45%
Upside
Reiterated
05/20/25
H.C. Wainwright
$65
Buy
38.95%
Upside
Reiterated
05/20/25
Goldman Sachs
$57→$47
Hold
0.47%
Upside
Reiterated
05/19/25
Citi
$82
Buy
75.29%
Upside
Reiterated
05/19/25
Bank of America Securities
$79
Buy
68.88%
Upside
Reiterated
05/19/25
Barclays
$56→$42
Hold
-10.22%
Downside
Reiterated
05/09/25
Best Analysts Covering Crispr Therapeutics AG
1 Month
xxx
Success Rate
12/18 ratings generated profit
Average Return
+9.43%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +9.43% per trade.
3 Months
xxx
Success Rate
11/19 ratings generated profit
Average Return
+5.54%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +5.54% per trade.
1 Year
Success Rate
18/40 ratings generated profit
Average Return
+19.41%
reiterated a buy rating 2 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of +19.41% per trade.
2 Years
xxx
Success Rate
15/40 ratings generated profit
Average Return
+1.15%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of +1.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CRSP Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
18
16
18
24
24
Buy
5
4
2
5
6
Hold
9
7
8
8
9
Sell
2
2
1
0
0
Strong Sell
0
0
0
0
0
total
34
29
29
37
39
Each month's total comprises the sum of three months' worth of ratings.
CRSP Financial Forecast
CRSP Stock Forecast FAQ
What is CRSP’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics AG’s 12-month average price target is 68.65.
What is CRSP’s upside potential, based on the analysts’ average price target?
Crispr Therapeutics AG has 46.75% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CRSP a Buy, Sell or Hold?
Crispr Therapeutics AG has a consensus rating of Moderate Buy which is based on 14 buy ratings, 6 hold ratings and 0 sell ratings.
What is Crispr Therapeutics AG’s price target?
The average price target for Crispr Therapeutics AG is 68.65. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $105.00 ,the lowest forecast is $35.00. The average price target represents 46.75% Increase from the current price of $46.78.
The highest analyst price target is $105.00 ,the lowest forecast is $35.00. The average price target represents 46.75% Increase from the current price of $46.78.
What do analysts say about Crispr Therapeutics AG?
Crispr Therapeutics AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.
How can I buy shares of CRSP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.